Polycystic Kidney Diseases in Adults
By:
Julie Xia Zhou Mayo Clinic, Division of Nephrology and Hypertension, Rochester, Minnesota

Search for other papers by Julie Xia Zhou in
Current site
Google Scholar
PubMed
Close
and
Vicente E. Torres Mayo Clinic, Division of Nephrology and Hypertension, Rochester, Minnesota

Search for other papers by Vicente E. Torres in
Current site
Google Scholar
PubMed
Close
  • Collapse
  • Expand
  • 1.

    Bergmann C, Guay-Woodford LM, Harris PC, Horie S, Peters DJM, Torres VE: Polycystic kidney disease. Nat Rev Dis Primers 4: 50, 2018 PubMed

  • 2.

    Drenth JP, te Morsche RH, Smink R, Bonifacino JS, Jansen JB: Germline mutations in PRKCSH are associated with autosomal dominant polycystic liver disease. Nat Genet 33: 345347, 2003 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Davila S, Furu L, Gharavi AG, Tian X, Onoe T, Qian Q, et al: Mutations in SEC63 cause autosomal dominant polycystic liver disease. Nat Genet 36: 575577, 2004 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Porath B, Gainullin VG, Cornec-Le Gall E, Dillinger EK, Heyer CM, Hopp K, et al; Genkyst Study Group, HALT Progression of Polycystic Kidney Disease Group; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease: Mutations in GANAB, encoding the glucosidase iiα subunit, cause autosomal-dominant polycystic kidney and liver disease. Am J Hum Genet 98: 11931207, 2016 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Besse W, Dong K, Choi J, Punia S, Fedeles SV, Choi M, et al: Isolated polycystic liver disease genes define effectors of polycystin-1 function. J Clin Invest 127: 17721785, 2017 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Lemoine H, Raud L, Foulquier F, Sayer JA, Lambert B, Olinger E, et al; Genomics England Research Consortium; Genkyst Study Group: Monoallelic pathogenic ALG5 variants cause atypical polycystic kidney disease and interstitial fibrosis. Am J Hum Genet 109: 14841499, 2022 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Besse W, Chang AR, Luo JZ, Triffo WJ, Moore BS, Gulati A, et al; Regeneron Genetics Center: ALG9 mutation carriers develop kidney and liver cysts. J Am Soc Nephrol 30: 20912102, 2019 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Senum SR, Li YSM, Benson KA, Joli G, Olinger E, Lavu S, et al; Genomics England Research Consortium, the HALT PKD, CRISP, DIPAK, ADPKD Modifier, and TAME PKD studies: Monoallelic IFT140 pathogenic variants are an important cause of the autosomal dominant polycystic kidney-spectrum phenotype. Am J Hum Genet 109: 136156, 2022 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Cornec-Le Gall E, Olson RJ, Besse W, Heyer CM, Gainullin VG, Smith JM, et al; Genkyst Study Group; HALT Progression of Polycystic Kidney Disease Group; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease: Monoallelic mutations to DNAJB11 cause atypical autosomal-dominant polycystic kidney disease. Am J Hum Genet 102: 832844, 2018 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Goggolidou P, Richards T: The genetics of autosomal recessive polycystic kidney disease (ARPKD). Biochim Biophys Acta Mol Basis Dis 1868: 166348, 2022 PubMed

  • 11.

    Dalgaard OZ: Bilateral polycystic disease of the kidneys; A follow-up of two hundred and eighty-four patients and their families. Acta Med Scand Suppl 328: 1255, 1957 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Iglesias CG, Torres VE, Offord KP, Holley KE, Beard CM, Kurland LT: Epidemiology of adult polycystic kidney disease, Olmsted County, Minnesota: 1935-1980. Am J Kidney Dis 2: 630639, 1983 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Suwabe T, Shukoor S, Chamberlain AM, Killian JM, King BF, Edwards M, et al: Epidemiology of autosomal dominant polycystic kidney disease in Olmsted County. Clin J Am Soc Nephrol 15: 6979, 2020 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14.

    Neumann HP, Jilg C, Bacher J, Nabulsi Z, Malinoc A, Hummel B, et al; Else-Kroener-Fresenius-ADPKD-Registry: Epidemiology of autosomal-dominant polycystic kidney disease: An in-depth clinical study for south-western Germany. Nephrol Dial Transplant 28: 14721487, 2013 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15.

    Willey CJ, Blais JD, Hall AK, Krasa HB, Makin AJ, Czerwiec FS: Prevalence of autosomal dominant polycystic kidney disease in the European Union. Nephrol Dial Transplant 32: 13561363, 2017 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16.

    Cornec-Le Gall E, Torres VE, Harris PC: Genetic complexity of autosomal dominant polycystic kidney and liver diseases. J Am Soc Nephrol 29: 1323, 2018 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17.

    Lanktree MB, Haghighi A, Guiard E, Iliuta IA, Song X, Harris PC, et al: Prevalence estimates of polycystic kidney and liver disease by population sequencing. J Am Soc Nephrol 29: 25932600, 2018 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18.

    Chang AR, Moore BS, Luo JZ, Sartori G, Fang B, Jacobs S, et al: Exome sequencing of a clinical population for autosomal dominant polycystic kidney disease. JAMA 328: 24122421, 2022 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 19.

    Parfrey PS, Bear JC, Morgan J, Cramer BC, McManamon PJ, Gault MH, et al: The diagnosis and prognosis of autosomal dominant polycystic kidney disease. N Engl J Med 323: 10851090, 1990 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 20.

    Hateboer N, v Dijk MA, Bogdanova N, Coto E, Saggar-Malik AK, San Millan JL, et al: Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1-PKD2 Study Group. Lancet 353: 103107, 1999 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 21.

    The International Polycystic Kidney Disease Consortium: Polycystic kidney disease: The complete structure of the PKD1 gene and its protein. Cell 81: 289298, 1995 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 22.

    Maser RL, Calvet JP: Adhesion GPCRs as a paradigm for understanding polycystin-1 G protein regulation. Cell Signal 72: 109637, 2020 PubMed

  • 23.

    Padovano V, Mistry K, Merrick D, Gresko N, Caplan MJ: A cut above (and below): Protein cleavage in the regulation of polycystin trafficking and signaling. Cell Signal 72: 109634, 2020 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 24.

    Hanaoka K, Qian F, Boletta A, Bhunia AK, Piontek K, Tsiokas L, et al: Co-assembly of polycystin-1 and -2 produces unique cation-permeable currents. Nature 408: 990994, 2000 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 25.

    Su Q, Hu F, Ge X, Lei J, Yu S, Wang T, et al: Structure of the human PKD1-PKD2 complex. Science 361: eaat9819, 2018 PubMed

  • 26.

    Outeda P, Huso DL, Fisher SA, Halushka MK, Kim H, Qian F, et al: Polycystin signaling is required for directed endothelial cell migration and lymphatic development. Cell Rep 7: 634644, 2014 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 27.

    Qian Q, Li M, Cai Y, Ward CJ, Somlo S, Harris PC, et al: Analysis of the polycystins in aortic vascular smooth muscle cells. J Am Soc Nephrol 14: 22802287, 2003 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 28.

    Dong K, Zhang C, Tian X, Coman D, Hyder F, Ma M, et al: Renal plasticity revealed through reversal of polycystic kidney disease in mice. Nat Genet 53: 16491663, 2021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 29.

    Qian F, Watnick TJ, Onuchic LF, Germino GG: The molecular basis of focal cyst formation in human autosomal dominant polycystic kidney disease type I. Cell 87: 979987, 1996 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 30.

    Wu G, D’Agati V, Cai Y, Markowitz G, Park JH, Reynolds DM, et al: Somatic inactivation of Pkd2 results in polycystic kidney disease. Cell 93: 177188, 1998 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 31.

    Watnick T, He N, Wang K, Liang Y, Parfrey P, Hefferton D, et al: Mutations of PKD1 in ADPKD2 cysts suggest a pathogenic effect of trans-heterozygous mutations. Nat Genet 25: 143144, 2000 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 32.

    Pei Y, Watnick T, He N, Wang K, Liang Y, Parfrey P, et al: Somatic PKD2 mutations in individual kidney and liver cysts support a “two-hit” model of cystogenesis in type 2 autosomal dominant polycystic kidney disease. J Am Soc Nephrol 10: 15241529, 1999 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 33.

    Zhang Z, Bai H, Blumenfeld J, Ramnauth AB, Barash I, Prince M, et al: Detection of PKD1 and PKD2 somatic variants in autosomal dominant polycystic kidney cyst epithelial cells by whole-genome sequencing. J Am Soc Nephrol 32: 31143129, 2021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 34.

    Ong AC, Harris PC: A polycystin-centric view of cyst formation and disease: The polycystins revisited. Kidney Int 88: 699710, 2015 PubMed

  • 35.

    Yamaguchi T, Nagao S, Wallace DP, Belibi FA, Cowley BD, Pelling JC, et al: Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys. Kidney Int 63: 19831994, 2003 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 36.

    Yamaguchi T, Wallace DP, Magenheimer BS, Hempson SJ, Grantham JJ, Calvet JP: Calcium restriction allows cAMP activation of the B-Raf/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype. J Biol Chem 279: 4041940430, 2004 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 37.

    Yamaguchi T, Hempson SJ, Reif GA, Hedge AM, Wallace DP: Calcium restores a normal proliferation phenotype in human polycystic kidney disease epithelial cells. J Am Soc Nephrol 17: 178187, 2006 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 38.

    Wang X, Wu Y, Ward CJ, Harris PC, Torres VE: Vasopressin directly regulates cyst growth in polycystic kidney disease. J Am Soc Nephrol 19: 102108, 2008 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 39.

    Zhou X, Torres VE: Emerging therapies for autosomal dominant polycystic kidney disease with a focus on cAMP signaling. Front Mol Biosci 9: 981963, 2022 10.3389/fmolb.2022.981963 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 40.

    Nowak KL, Hopp K: Metabolic reprogramming in autosomal dominant polycystic kidney disease: Evidence and therapeutic potential. Clin J Am Soc Nephrol 15: 577584, 2020 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 41.

    Yang B, Sonawane ND, Zhao D, Somlo S, Verkman AS: Small-molecule CFTR inhibitors slow cyst growth in polycystic kidney disease. J Am Soc Nephrol 19: 13001310, 2008 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 42.

    Hanaoka K, Guggino WB: cAMP regulates cell proliferation and cyst formation in autosomal polycystic kidney disease cells. J Am Soc Nephrol 11: 11791187, 2000 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 43.

    Kunzelmann K: The cystic fibrosis transmembrane conductance regulator and its function in epithelial transport. Rev Physiol Biochem Pharmacol 137: 170, 1999 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 44.

    O’Sullivan DA, Torres VE, Gabow PA, Thibodeau SN, King BF, Bergstralh EJ: Cystic fibrosis and the phenotypic expression of autosomal dominant polycystic kidney disease. Am J Kidney Dis 32: 976983, 1998 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 45.

    Xu N, Glockner JF, Rossetti S, Babovich-Vuksanovic D, Harris PC, Torres VE: Autosomal dominant polycystic kidney disease coexisting with cystic fibrosis. J Nephrol 19: 529534, 2006 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 46.

    Cabrita I, Kraus A, Scholz JK, Skoczynski K, Schreiber R, Kunzelmann K, et al: Cyst growth in ADPKD is prevented by pharmacological and genetic inhibition of TMEM16A in vivo. Nat Commun 11: 4320, 2020 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 47.

    Albaqumi M, Srivastava S, Li Z, Zhdnova O, Wulff H, Itani O, et al: KCa3.1 potassium channels are critical for cAMP-dependent chloride secretion and cyst growth in autosomal-dominant polycystic kidney disease. Kidney Int 74: 740749, 2008 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 48.

    Sullivan LP, Wallace DP, Gover T, Welling PA, Yamaguchi T, Maser R, et al: Sulfonylurea-sensitive K(+) transport is involved in Cl(-) secretion and cyst trowth by cultured ADPKD cells. J Am Soc Nephrol 13: 26192627, 2002 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 49.

    Gabow PA, Kaehny WD, Johnson AM, Duley IT, Manco-Johnson M, Lezotte DC, et al: The clinical utility of renal concentrating capacity in polycystic kidney disease. Kidney Int 35: 675680, 1989 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 50.

    Seeman T, Dusek J, Vondrák K, Bláhová K, Simková E, Kreisinger J, et al: Renal concentrating capacity is linked to blood pressure in children with autosomal dominant polycystic kidney disease. Physiol Res 53: 629634, 2004 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 51.

    Torres VE: Vasopressin antagonists in polycystic kidney disease. Kidney Int 68: 24052418, 2005 PubMed

  • 52.

    Ecder T, Schrier RW: Hypertension in autosomal-dominant polycystic kidney disease: Early occurrence and unique aspects. J Am Soc Nephrol 12: 194200, 2001 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 53.

    Chapman AB, Johnson A, Gabow PA, Schrier RW: The renin-angiotensin-aldosterone system and autosomal dominant polycystic kidney disease. N Engl J Med 323: 10911096, 1990 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 54.

    Bell PE, Hossack KF, Gabow PA, Durr JA, Johnson AM, Schrier RW: Hypertension in autosomal dominant polycystic kidney disease. Kidney Int 34: 683690, 1988 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 55.

    Massella L, Mekahli D, Paripović D, Prikhodina L, Godefroid N, Niemirska A, et al: Prevalence of hypertension in children with early-stage ADPKD. Clin J Am Soc Nephrol 13: 874883, 2018 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 56.

    Barrett BJ, Foley R, Morgan J, Hefferton D, Parfrey P: Differences in hormonal and renal vascular responses between normotensive patients with autosomal dominant polycystic kidney disease and unaffected family members. Kidney Int 46: 11181123, 1994 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 57.

    Chapman AB, Bost JE, Torres VE, Guay-Woodford L, Bae KT, Landsittel D, et al: Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 7: 479486, 2012 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 58.

    Brosnahan GM, Abebe KZ, Moore CG, Rahbari-Oskoui FF, Bae KT, Grantham JJ, et al; HALT-PKD Trial Investigators: Patterns of kidney function decline in autosomal dominant polycystic kidney disease: A post hoc analysis from the HALT-PKD trials. Am J Kidney Dis 71: 666676, 2018 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 59.

    Shukoor SS, Vaughan LE, Edwards ME, Lavu S, Kline TL, Senum SR, et al: Characteristics of patients with end-stage kidney disease in ADPKD. Kidney Int Rep 6: 755767, 2020 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 60.

    Gabow PA, Duley I, Johnson AM: Clinical profiles of gross hematuria in autosomal dominant polycystic kidney disease. Am J Kidney Dis 20: 140143, 1992 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 61.

    Torres VE, Wilson DM, Hattery RR, Segura JW: Renal stone disease in autosomal dominant polycystic kidney disease. Am J Kidney Dis 22: 513519, 1993 PubMed

  • 62.

    Grampsas SA, Chandhoke PS, Fan J, Glass MA, Townsend R, Johnson AM, et al: Anatomic and metabolic risk factors for nephrolithiasis in patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis 36: 5357, 2000 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 63.

    Nishiura JL, Neves RF, Eloi SR, Cintra SM, Ajzen SA, Heilberg IP: Evaluation of nephrolithiasis in autosomal dominant polycystic kidney disease patients. Clin J Am Soc Nephrol 4: 838844, 2009 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 64.

    Uribarri J: Chronic kidney disease and kidney stones. Curr Opin Nephrol Hypertens 29: 237242, 2020 PubMed

  • 65.

    Torres JA, Rezaei M, Broderick C, Lin L, Wang X, Hoppe B, et al: Crystal deposition triggers tubule dilation that accelerates cystogenesis in polycystic kidney disease. J Clin Invest 129: 45064522, 2019 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 66.

    Sallée M, Rafat C, Zahar JR, Paulmier B, Grünfeld JP, Knebelmann B, et al: Cyst infections in patients with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 4: 11831189, 2009 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 67.

    Orskov B, Sørensen VR, Feldt-Rasmussen B, Strandgaard S: Changes in causes of death and risk of cancer in Danish patients with autosomal dominant polycystic kidney disease and end-stage renal disease. Nephrol Dial Transplant 27: 16071613, 2012 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 68.

    Wetmore JB, Calvet JP, Yu AS, Lynch CF, Wang CJ, Kasiske BL, et al: Polycystic kidney disease and cancer after renal transplantation. J Am Soc Nephrol 25: 23352341, 2014 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 69.

    Yu TM, Chuang YW, Yu MC, Chen CH, Yang CK, Huang ST, et al: Risk of cancer in patients with polycystic kidney disease: A propensity-score matched analysis of a nationwide, population-based cohort study. Lancet Oncol 17: 14191425, 2016 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 70.

    Bae KT, Zhu F, Chapman AB, Torres VE, Grantham JJ, Guay-Woodford LM, et al; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP): Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort. Clin J Am Soc Nephrol 1: 6469, 2006 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 71.

    Gabow PA, Johnson AM, Kaehny WD, Manco-Johnson ML, Duley IT, Everson GT: Risk factors for the development of hepatic cysts in autosomal dominant polycystic kidney disease. Hepatology 11: 10331037, 1990 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 72.

    Everson GT: Hepatic cysts in autosomal dominant polycystic kidney disease. Am J Kidney Dis 22: 520525, 1993 PubMed

  • 73.

    Sherstha R, McKinley C, Russ P, Scherzinger A, Bronner T, Showalter R, et al: Postmenopausal estrogen therapy selectively stimulates hepatic enlargement in women with autosomal dominant polycystic kidney disease. Hepatology 26: 12821286, 1997 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 74.

    Chebib FT, Jung Y, Heyer CM, Irazabal MV, Hogan MC, Harris PC, et al: Effect of genotype on the severity and volume progression of polycystic liver disease in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 31: 952960, 2016 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 75.

    Sanchis IM, Shukoor S, Irazabal MV, Madsen CD, Chebib FT, Hogan MC, et al: Presymptomatic screening for intracranial aneurysms in patients with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 14: 11511160, 2019 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 76.

    Schrier RW, Belz MM, Johnson AM, Kaehny WD, Hughes RL, Rubinstein D, et al: Repeat imaging for intracranial aneurysms in patients with autosomal dominant polycystic kidney disease with initially negative studies: A prospective ten-year follow-up. J Am Soc Nephrol 15: 10231028, 2004 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 77.

    Jiang T, Wang P, Qian Y, Zheng X, Xiao L, Yu S, et al: A follow-up study of autosomal dominant polycystic kidney disease with intracranial aneurysms using 3.0 T three-dimensional time-of-flight magnetic resonance angiography. Eur J Radiol 82: 18401845, 2013 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 78.

    Flahault A, Trystram D, Nataf F, Fouchard M, Knebelmann B, Grünfeld JP, et al: Screening for intracranial aneurysms in autosomal dominant polycystic kidney disease is cost-effective. Kidney Int 93: 716726, 2018 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 79.

    Etminan N, Chang HS, Hackenberg K, de Rooij NK, Vergouwen MDI, Rinkel GJE, et al: Worldwide incidence of aneurysmal subarachnoid hemorrhage according to region, time period, blood pressure, and smoking prevalence in the population: A systematic review and meta-analysis. JAMA Neurol 76: 588597, 2019 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 80.

    Biagini A, Maffei S, Baroni M, Piacenti M, Terrazzi M, Paoli F, et al: Familiar clustering of aortic dissection in polycystic kidney disease. Am J Cardiol 72: 741742, 1993 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 81.

    Inaba Y, Osako M, Aoki M, Kasai M, Yamabe K: Aortic dissection in familial patients with autosomal dominant polycystic kidney disease. Ann Vasc Dis 14: 6870, 2021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 82.

    Bouleti C, Flamant M, Escoubet B, Arnoult F, Milleron O, Vidal-Petiot E, et al: Risk of ascending aortic aneurysm in patients with autosomal dominant polycystic kidney disease. Am J Cardiol 123: 482488, 2019 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 83.

    Chedid M, Kaidbay HD, Wigerinck S, Mkhaimer Y, Smith B, Zubidat D, et al: Cardiovascular outcomes in kidney transplant recipients with ADPKD. Kidney Int Rep 7: 19912005, 2022 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 84.

    Sung PH, Yang YH, Chiang HJ, Chiang JY, Chen CJ, Liu CT, et al: Risk of aortic aneurysm and dissection in patients with autosomal-dominant polycystic kidney disease: A nationwide population-based cohort study. Oncotarget 8: 5759457604, 2017 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 85.

    Chapman AB, Johnson AM, Rainguet S, Hossack K, Gabow P, Schrier RW: Left ventricular hypertrophy in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 8: 12921297, 1997 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 86.

    Perrone RD, Abebe KZ, Schrier RW, Chapman AB, Torres VE, Bost J, et al; HALT PKD Study Group: Cardiac magnetic resonance assessment of left ventricular mass in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 6: 25082515, 2011 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 87.

    Hossack KF, Leddy CL, Johnson AM, Schrier RW, Gabow PA: Echocardiographic findings in autosomal dominant polycystic kidney disease. N Engl J Med 319: 907912, 1988 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 88.

    Qian Q, Hartman RP, King BF, Torres VE: Increased occurrence of pericardial effusion in patients with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2: 12231227, 2007 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 89.

    Chedid M, Hanna C, Zaatari G, Mkhaimer Y, Reddy P, Rangel L, et al: Congenital heart disease in adults with autosomal dominant polycystic kidney disease. Am J Nephrol 53: 316324, 2022 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 90.

    Chebib FT, Hogan MC, El-Zoghby ZM, Irazabal MV, Senum SR, Heyer CM, et al: Autosomal dominant polycystic kidney patients may be predisposed to various cardiomyopathies. Kidney Int Rep 2: 913923, 2017 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 91.

    McNicholas BA, Kotaro Y, Martin W, Sharma A, Kamath PS, Edwards ME, et al: Pancreatic cysts and intraductal papillary mucinous neoplasm in autosomal dominant polycystic kidney disease. Pancreas 48: 698705, 2019 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 92.

    Wijdicks EF, Torres VE, Schievink WI: Chronic subdural hematoma in autosomal dominant polycystic kidney disease. Am J Kidney Dis 35: 4043, 2000 PubMed

  • 93.

    Torra R, Sarquella J, Calabia J, Martí J, Ars E, Fernández-Llama P, et al: Prevalence of cysts in seminal tract and abnormal semen parameters in patients with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 3: 790793, 2008 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 94.

    Morris-Stiff G, Coles G, Moore R, Jurewicz A, Lord R: Abdominal wall hernia in autosomal dominant polycystic kidney disease. Br J Surg 84: 615617, 1997 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 95.

    Modi KB, Grant AC, Garret A, Rodger RS: Indirect inguinal hernia in CAPD patients with polycystic kidney disease. Adv Perit Dial 5: 8486, 1989 PubMed

  • 96.

    Sharp CK, Zeligman BE, Johnson AM, Duley I, Gabow PA: Evaluation of colonic diverticular disease in autosomal dominant polycystic kidney disease without end-stage renal disease. Am J Kidney Dis 34: 863868, 1999 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 97.

    Scheff RT, Zuckerman G, Harter H, Delmez J, Koehler R: Diverticular disease in patients with chronic renal failure due to polycystic kidney disease. Ann Intern Med 92: 202204, 1980 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 98.

    Kumar S, Adeva M, King BF, Kamath PS, Torres VE: Duodenal diverticulosis in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 21: 35763578, 2006 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 99.

    Moua T, Zand L, Hartman RP, Hartman TE, Qin D, Peikert T, et al: Radiologic and clinical bronchiectasis associated with autosomal dominant polycystic kidney disease. PLoS One 9: e93674, 2014 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 100.

    Liu J, Yin X, Dev H, Luo X, Blumenfeld JD, Rennert H, et al: Pleural effusions on MRI in autosomal dominant polycystic kidney disease. J Clin Med 12: 386, 2023 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 101.

    Nicolau C, Torra R, Badenas C, Vilana R, Bianchi L, Gilabert R, et al: Autosomal dominant polycystic kidney disease types 1 and 2: Assessment of US sensitivity for diagnosis. Radiology 213: 273276, 1999 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 102.

    Ravine D, Gibson RN, Walker RG, Sheffield LJ, Kincaid-Smith P, Danks DM: Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1. Lancet 343: 824827, 1994 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 103.

    Pei Y, Obaji J, Dupuis A, Paterson AD, Magistroni R, Dicks E, et al: Unified criteria for ultrasonographic diagnosis of ADPKD. J Am Soc Nephrol 20: 205212, 2009 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 104.

    Pei Y, Hwang YH, Conklin J, Sundsbak JL, Heyer CM, Chan W, et al: Imaging-based diagnosis of autosomal dominant polycystic kidney disease. J Am Soc Nephrol 26: 746753, 2015 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 105.

    Chebib FT, Torres VE: Autosomal dominant polycystic kidney disease: Core curriculum 2016. Am J Kidney Dis 67: 792810, 2016 PubMed

  • 106.

    Ravine D, Gibson RN, Donlan J, Sheffield LJ: An ultrasound renal cyst prevalence survey: Specificity data for inherited renal cystic diseases. Am J Kidney Dis 22: 803807, 1993 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 107.

    Slywotzky CM, Bosniak MA: Localized cystic disease of the kidney. AJR Am J Roentgenol 176: 843849, 2001 PubMed

  • 108.

    Levine E: Acquired cystic kidney disease. Radiol Clin North Am 34: 947964, 1996 PubMed

  • 109.

    Gulati A, Sevillano AM, Praga M, Gutierrez E, Alba I, Dahl NK, et al: Collagen IV gene mutations in adults with bilateral renal cysts and CKD. Kidney Int Rep 5: 103108, 2019 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 110.

    Plaisier E, Gribouval O, Alamowitch S, Mougenot B, Prost C, Verpont MC, et al: COL4A1 mutations and hereditary angiopathy, nephropathy, aneurysms, and muscle cramps. N Engl J Med 357: 26872695, 2007 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 111.

    Murray KK, McLellan GL: Renal peripelvic lymphangiectasia: Appearance at CT. Radiology 180: 455456, 1991 PubMed

  • 112.

    Gambaro G, Feltrin GP, Lupo A, Bonfante L, D’Angelo A, Antonello A: Medullary sponge kidney (Lenarduzzi-Cacchi-Ricci disease): A Padua Medical School discovery in the 1930s. Kidney Int 69: 663670, 2006 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 113.

    Sampson JR, Maheshwar MM, Aspinwall R, Thompson P, Cheadle JP, Ravine D, et al: Renal cystic disease in tuberous sclerosis: Role of the polycystic kidney disease 1 gene. Am J Hum Genet 61: 843851, 1997 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 114.

    Gambella A, Kalantari S, Cadamuro M, Quaglia M, Delvecchio M, Fabris L, et al: The landscape of HNF1B deficiency: A syndrome not yet fully explored. Cells 12: 307, 2023 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 115.

    Thauvin-Robinet C, Cossée M, Cormier-Daire V, Van Maldergem L, Toutain A, Alembik Y, et al: Clinical, molecular, and genotype-phenotype correlation studies from 25 cases of oral-facial-digital syndrome type 1: A French and Belgian collaborative study. J Med Genet 43: 5461, 2006 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 116.

    Murphy EL, Droher ML, DiMaio MS, Dahl NK: Preimplantation genetic diagnosis counseling in autosomal dominant polycystic kidney disease. Am J Kidney Dis 72: 866872, 2018 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 117.

    McBride L, Wilkinson C, Jesudason S: Management of autosomal dominant polycystic kidney disease (ADPKD) during pregnancy: Risks and challenges. Int J Womens Health 12: 409422, 2020 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 118.

    In: Hypertension in pregnancy: diagnosis and management. NICE guideline London 2019. https://www.nice.org.uk/guidance/ng133

    • PubMed
    • Export Citation
  • 119.

    Barash I, Ponda MP, Goldfarb DS, Skolnik EY: A pilot clinical study to evaluate changes in urine osmolality and urine cAMP in response to acute and chronic water loading in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 5: 693697, 2010 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 120.

    Rangan GK, Wong ATY, Munt A, et al. Prescribed water intake in autosomal dominant polycystic kidney disease. NEJM Evidence 1, 2021 Available at https://evidence.nejm.org/doi/full/10.1056/EVIDoa21000212021 10.1056/EVIDoa2100021.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 121.

    Chapman AB, Torres VE, Perrone RD, Steinman TI, Bae KT, Miller JP, et al: The HALT polycystic kidney disease trials: Design and implementation. Clin J Am Soc Nephrol 5: 102109, 2010 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 122.

    Torres VE, Abebe KZ, Schrier RW, Perrone RD, Chapman AB, Yu AS, et al: Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease. Kidney Int 91: 493500, 2017 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 123.

    Kramers BJ, Koorevaar IW, Drenth JPH, de Fijter JW, Neto AG, Peters DJM, et al: Salt, but not protein intake, is associated with accelerated disease progression in autosomal dominant polycystic kidney disease. Kidney Int 98: 989998, 2020 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 124.

    Irazabal MV, Abebe KZ, Bae KT, Perrone RD, Chapman AB, Schrier RW, et al; HALT Investigators: Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: The HALT-PKD clinical trial. Nephrol Dial Transplant 32: 18571865, 2017 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 125.

    Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, et al; TEMPO 3:4 Trial Investigators: Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 367: 24072418, 2012 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 126.

    Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Dandurand A, et al; TEMPO 4:4 Trial Investigators: Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: The TEMPO 4:4 Trial. Nephrol Dial Transplant 33: 477489, 2018 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 127.

    Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Koch G, et al; REPRISE Trial Investigators: Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N Engl J Med 377: 19301942, 2017 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 128.

    Irazabal MV, Rangel LJ, Bergstralh EJ, Osborn SL, Harmon AJ, Sundsbak JL, et al; CRISP Investigators: Imaging classification of autosomal dominant polycystic kidney disease: A simple model for selecting patients for clinical trials. J Am Soc Nephrol 26: 160172, 2015 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 129.

    Cornec-Le Gall E, Audrézet MP, Rousseau A, Hourmant M, Renaudineau E, Charasse C, et al: The PROPKD score: A new algorithm to predict renal survival in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 27: 942951, 2016 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 130.

    Kramers BJ, Koorevaar IW, van Gastel MDA, van Goor H, Hallows KR, Heerspink HL, et al: Effects of hydrochlorothiazide and metformin on aquaresis and nephroprotection by a vasopressin V2 receptor antagonist in ADPKD: A randomized crossover trial. Clin J Am Soc Nephrol 17: 507517, 2022 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 131.

    Chebib FT, Perrone RD, Chapman AB, Dahl NK, Harris PC, Mrug M, et al: A practical guide for treatment of rapidly progressive ADPKD with tolvaptan. J Am Soc Nephrol 29: 24582470, 2018 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 132.

    Shoaf SE, Bricmont P, Repella Gordon J: Regulatory guidelines do not accurately predict tolvaptan and metabolite interactions at BCRP, OATP1B1, and OAT3 transporters. Clin Transl Sci 14: 15351542, 2021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 133.

    Shoaf SE, Ouyang J, Sergeyeva O, Estilo A, Li H, Leung D: A post hoc analysis of statin use in tolvaptan autosomal dominant polycystic kidney disease pivotal trials. Clin J Am Soc Nephrol 15: 643650, 2020 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 134.

    Shoaf SE, Chapman AB, Torres VE, Ouyang J, Czerwiec FS: Pharmacokinetics and pharmacodynamics of tolvaptan in autosomal dominant polycystic kidney disease: Phase 2 trials for dose selection in the pivotal phase 3 trial. J Clin Pharmacol 57: 906917, 2017 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 135.

    Kramers BJ, van Gastel MDA, Boertien WE, Meijer E, Gansevoort RT: Determinants of urine volume in ADPKD patients using the vasopressin V2 receptor antagonist tolvaptan. Am J Kidney Dis 73: 354362, 2019 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 136.

    Alpers DH, Lewis JH, Hunt CM, Freston JW, Torres VE, Li H, et al: Clinical pattern of tolvaptan-associated liver injury in trial participants with autosomal dominant polycystic kidney disease (ADPKD): An analysis of pivotal clinical trials. Am J Kidney Dis 81: 281293.e1, 2023 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 137.

    Rodríguez-Espinosa D, Broseta JJ, Bastida C, Álvarez-Mora MI, Nicolau C, Alvarez C, et al: Creatine kinase elevation in autosomal dominant polycystic kidney disease patients on tolvaptan treatment. Nephron 147: 152157, 2023.PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 138.

    Aiello V, Fusaroli M, Raschi E, Palazzini M, Hu L, Barbuto S, et al: Pulmonary Embolism in a patient with ADPKD treated with tolvaptan: From the clinical experience to the analysis of the Food and Drug Administration Adverse Event Reporting System Registry. Kidney Int Rep 6: 24722477, 2021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 139.

    Caroli A, Perico N, Perna A, Antiga L, Brambilla P, Pisani A, et al; ALADIN study group: Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): A randomised, placebo-controlled, multicentre trial. Lancet 382: 14851495, 2013 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 140.

    Perico N, Ruggenenti P, Perna A, Caroli A, Trillini M, Sironi S, et al; ALADIN 2 Study Group: Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial. PLoS Med 16: e1002777, 2019 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 141.

    Meijer E, Visser FW, van Aerts RMM, Blijdorp CJ, Casteleijn NF, D’Agnolo HMA, et al; DIPAK-1 Investigators: Effect of lanreotide on kidney function in patients with autosomal dominant polycystic kidney disease: The DIPAK 1 randomized clinical trial. JAMA 320: 20102019, 2018 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 142.

    Trillini M, Caroli A, Perico N, Remuzzi A, Brambilla P, Villa G, et al; TOOL Study Group: Effects of octreotide-long-acting release added-on tolvaptan in patients with autosomal dominant polycystic kidney disease: Pilot, randomized, placebo-controlled, cross-over trial. Clin J Am Soc Nephrol 18: 223233, 2023 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 143.

    Kalatharan V, Jandoc R, Grewal G, Nash DM, Welk B, Sarma S, et al: Efficacy and safety of surgical kidney stone interventions in autosomal dominant polycystic kidney disease: A systematic review. Can J Kidney Health Dis 7: 2054358120940433, 2020 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 144.

    Peces R, Aguilar A, Vega C, Cuesta E, Peces C, Selgas R: Medical therapy with tranexamic acid in autosomal dominant polycystic kidney disease patients with severe haematuria. Nefrologia 32: 160165, 2012 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 145.

    Suwabe T, Ubara Y, Sumida K, Hayami N, Hiramatsu R, Yamanouchi M, et al: Clinical features of cyst infection and hemorrhage in ADPKD: New diagnostic criteria. Clin Exp Nephrol 16: 892902, 2012 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 146.

    Jouret F, Lhommel R, Devuyst O, Annet L, Pirson Y, Hassoun Z, et al: Diagnosis of cyst infection in patients with autosomal dominant polycystic kidney disease: Attributes and limitations of the current modalities. Nephrol Dial Transplant 27: 37463751, 2012 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 147.

    Dang J, Scemla A, Loheac C, Chaba A, Bienaimé F, Joly D, et al: Efficacy of prolonged antibiotic therapy for renal cyst infections in polycystic kidney disease. Mayo Clin Proc 97: 13051317, 2022 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 148.

    LeMaire SA, Zhang L, Zhang NS, Luo W, Barrish JP, Zhang Q, et al: Ciprofloxacin accelerates aortic enlargement and promotes dissection and rupture in Marfan mice. J Thorac Cardiovasc Surg 163: e215e226, 2022 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 149.

    Son N, Choi E, Chung SY, Han SY, Kim B: Risk of aortic aneurysm and aortic dissection with the use of fluoroquinolones in Korea: A nested case-control study. BMC Cardiovasc Disord 22: 44, 2022 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 150.

    Bajwa ZH, Gupta S, Warfield CA, Steinman TI: Pain management in polycystic kidney disease. Kidney Int 60: 16311644, 2001 PubMed

  • 151.

    Iliuta IA, Shi B, Pourafkari M, Akbari P, Bruni G, Hsiao R, et al: Foam sclerotherapy for cyst volume reduction in autosomal dominant polycystic kidney disease: A prospective cohort study. Kidney Med 1: 366375, 2019 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 152.

    Haseebuddin M, Tanagho YS, Millar M, Roytman T, Chen C, Clayman RV, et al: Long-term impact of laparoscopic cyst decortication on renal function, hypertension and pain control in patients with autosomal dominant polycystic kidney disease. J Urol 188: 12391244, 2012 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 153.

    Fryczkowski M, Huk J, Sitko-Saucha A, Kupilas A: [Place of laparoscopic cysts decortication (LCD) in the treatment of autosomal dominant polycystic kidney disease (AD PKD)]. Prog Urol 17: 13241327, 2007 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 154.

    de Jager RL, Casteleijn NF, de Beus E, Bots ML, Vonken EE, Gansevoort RT, et al: Catheter-based renal denervation as therapy for chronic severe kidney-related pain. Nephrol Dial Transplant 33: 614619, 2018 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 155.

    Casteleijn NF, Visser FW, Drenth JP, et al. A stepwise approach for effective management of chronic pain in autosomal-dominant polycystic kidney disease. Nephrol Dial Transplant 29 (Suppl 4): iv142153, 2014.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 156.

    van Luijk F, Gansevoort RT, Blokzijl H, Groen GJ, de Haas RJ, Leliveld AM, et al: Multidisciplinary management of chronic refractory pain in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 38: 618629, 2023 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 157.

    Hadimeri H, Nordén G, Friman S, Nyberg G: Autosomal dominant polycystic kidney disease in a kidney transplant population. Nephrol Dial Transplant 12: 14311436, 1997 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 158.

    Andreoni KA, Pelletier RP, Elkhammas EA, Davies EA, Bumgardner GL, Henry ML, et al: Increased incidence of gastrointestinal surgical complications in renal transplant recipients with polycystic kidney disease. Transplantation 67: 262266, 1999 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 159.

    Jung Y, Irazabal MV, Chebib FT, Harris PC, Dean PG, Prieto M, et al: Volume regression of native polycystic kidneys after renal transplantation. Nephrol Dial Transplant 31: 7379, 2016 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 160.

    Abrol N, Bentall A, Torres VE, Prieto M: Simultaneous bilateral laparoscopic nephrectomy with kidney transplantation in patients with ESRD due to ADPKD: A single-center experience. Am J Transplant 21: 15131524, 2021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 161.

    Pirson Y, Christophe JL, Goffin E: Outcome of renal replacement therapy in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 11[Suppl 6]: 2428, 1996 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 162.

    Perrone RD, Ruthazer R, Terrin NC: Survival after end-stage renal disease in autosomal dominant polycystic kidney disease: Contribution of extrarenal complications to mortality. Am J Kidney Dis 38: 777784, 2001 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 163.

    Shaw C, Simms RJ, Pitcher D, Sandford R: Epidemiology of patients in England and Wales with autosomal dominant polycystic kidney disease and end-stage renal failure. Nephrol Dial Transplant 29: 19101918, 2014 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 164.

    Kraus A, Peters DJM, Klanke B, Weidemann A, Willam C, Schley G, et al: HIF-1α promotes cyst progression in a mouse model of autosomal dominant polycystic kidney disease. Kidney Int 94: 887899, 2018 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 165.

    Sigogne M, Kanagaratnam L, Dupont V, Couchoud C, Verger C, Maheut H, et al: Outcome of autosomal dominant polycystic kidney disease patients on peritoneal dialysis: A national retrospective study based on two French registries (the French Language Peritoneal Dialysis Registry and the French Renal Epidemiology and Information Network). Nephrol Dial Transplant 33: 20202026, 2018 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 166.

    Dupont V, Kanagaratnam L, Sigogne M, Bechade C, Lobbedez T, Portoles J, et al: Outcome of polycystic kidney disease patients on peritoneal dialysis: Systematic review of literature and meta-analysis. PLoS One 13: e0196769, 2018 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 167.

    Schnelldorfer T, Torres VE, Zakaria S, Rosen CB, Nagorney DM: Polycystic liver disease: A critical appraisal of hepatic resection, cyst fenestration, and liver transplantation. Ann Surg 250: 112118, 2009 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 168.

    Chebib FT, Harmon A, Irazabal Mira MV, Jung YS, Edwards ME, Hogan MC, et al: Outcomes and durability of hepatic reduction after combined partial hepatectomy and cyst fenestration for massive polycystic liver disease. J Am Coll Surg 223: 118126.e1, 2016 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 169.

    Mekeel KL, Moss AA, Reddy KS, Douglas DD, Vargas HE, Carey EJ, et al: Living donor liver transplantation in polycystic liver disease. Liver Transpl 14: 680683, 2008 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 170.

    Takei R, Ubara Y, Hoshino J, Higa Y, Suwabe T, Sogawa Y, et al: Percutaneous transcatheter hepatic artery embolization for liver cysts in autosomal dominant polycystic kidney disease. Am J Kidney Dis 49: 744752, 2007 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 171.

    van Aerts RMM, Kievit W, D’Agnolo HMA, Blijdorp CJ, Casteleijn NF, Dekker SEI, et al; DIPAK-1 Investigators: Lanreotide reduces liver growth in patients with autosomal dominant polycystic liver and kidney disease. Gastroenterology 157: 481491.e7, 2019 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 172.

    Pisani A, Sabbatini M, Imbriaco M, Riccio E, Rubis N, Prinster A, et al; ALADIN Study Group: Long-term effects of octreotide on liver volume in patients with polycystic kidney and liver disease. Clin Gastroenterol Hepatol 14: 10221030.e4, 2016 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 173.

    Hogan MC, Masyuk TV, Page LJ, Kubly VJ, Bergstralh EJ, Li X, et al: Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol 21: 10521061, 2010 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 174.

    Hogan MC, Masyuk TV, Page L, Holmes DR 3rd, Li X, Bergstralh EJ, et al: Somatostatin analog therapy for severe polycystic liver disease: Results after 2 years. Nephrol Dial Transplant 27: 35323539, 2012 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 175.

    Caroli A, Antiga L, Cafaro M, Fasolini G, Remuzzi A, Remuzzi G, et al: Reducing polycystic liver volume in ADPKD: Effects of somatostatin analogue octreotide. Clin J Am Soc Nephrol 5: 783789, 2010 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 176.

    Hogan MC, Chamberlin JA, Vaughan LE, Waits AL, Banks C, Leistikow K, et al: Pansomatostatin agonist pasireotide long-acting release for patients with autosomal dominant polycystic kidney or liver disease with severe liver involvement: A randomized clinical trial. Clin J Am Soc Nephrol 15: 12671278, 2020 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 177.

    Chapman AB, Devuyst O, Eckardt KU, Gansevoort RT, Harris T, Horie S, et al; Conference Participants: Autosomal-dominant polycystic kidney disease (ADPKD): Executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 88: 1727, 2015 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 178.

    Schievink WI, Torres VE, Piepgras DG, Wiebers DO: Saccular intracranial aneurysms in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 3: 8895, 1992 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 179.

    Malhotra A, Wu X, Matouk CC, Forman HP, Gandhi D, Sanelli P: MR angiography screening and surveillance for intracranial aneurysms in autosomal dominant polycystic kidney disease: A cost-effectiveness analysis. Radiology 291: 400408, 2019 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 180.

    Bederson JB, Awad IA, Wiebers DO, Piepgras D, Haley EC Jr, Brott T, et al: Recommendations for the management of patients with unruptured intracranial aneurysms: A statement for healthcare professionals from the Stroke Council of the American Heart Association. Circulation 102: 23002308, 2000 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 181.

    Burgmaier K, Brinker L, Erger F, Beck BB, Benz MR, Bergmann C, et al; ESCAPE Study group; GPN study group; ARegPKD consortium: Refining genotype-phenotype correlations in 304 patients with autosomal recessive polycystic kidney disease and PKHD1 gene variants. Kidney Int 100: 650659, 2021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 182.

    Olson RJ, Hopp K, Wells H, Smith JM, Furtado J, Constans MM, et al: Synergistic genetic interactions between Pkhd1 and Pkd1 result in an ARPKD-like phenotype in murine models. J Am Soc Nephrol 30: 21132127, 2019 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 183.

    Cordido A, Vizoso-Gonzalez M, Garcia-Gonzalez MA: Molecular pathophysiology of autosomal recessive polycystic kidney disease. Int J Mol Sci 22: 6523, 2021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 184.

    Burgmaier K, Kilian S, Bammens B, Benzing T, Billing H, Büscher A, et al: Clinical courses and complications of young adults with autosomal recessive polycystic kidney disease (ARPKD). Sci Rep 9: 7919, 2019 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 185.

    Adeva M, El-Youssef M, Rossetti S, Kamath PS, Kubly V, Consugar MB, et al: Clinical and molecular characterization defines a broadened spectrum of autosomal recessive polycystic kidney disease (ARPKD). Medicine (Baltimore) 85: 121, 2006 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 186.

    Gunay-Aygun